CN111565714B - 包含依维莫司的实现稳定化的药剂学制剂 - Google Patents

包含依维莫司的实现稳定化的药剂学制剂 Download PDF

Info

Publication number
CN111565714B
CN111565714B CN201980007209.1A CN201980007209A CN111565714B CN 111565714 B CN111565714 B CN 111565714B CN 201980007209 A CN201980007209 A CN 201980007209A CN 111565714 B CN111565714 B CN 111565714B
Authority
CN
China
Prior art keywords
everolimus
particles
preparing
pharmaceutical formulation
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980007209.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN111565714A (zh
Inventor
韩敬姬
金暋洙
朴信政
林宗来
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chong Kun Dang Corp
Original Assignee
Chong Kun Dang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Corp filed Critical Chong Kun Dang Corp
Publication of CN111565714A publication Critical patent/CN111565714A/zh
Application granted granted Critical
Publication of CN111565714B publication Critical patent/CN111565714B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41A—FUNCTIONAL FEATURES OR DETAILS COMMON TO BOTH SMALLARMS AND ORDNANCE, e.g. CANNONS; MOUNTINGS FOR SMALLARMS OR ORDNANCE
    • F41A17/00—Safety arrangements, e.g. safeties
    • F41A17/42—Safeties for locking the breech-block or bolt in a safety position
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
CN201980007209.1A 2018-01-12 2019-01-07 包含依维莫司的实现稳定化的药剂学制剂 Active CN111565714B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020180004458A KR102051806B1 (ko) 2018-01-12 2018-01-12 에베로리무스를 포함하는 안정화된 약제학적 제제
KR10-2018-0004458 2018-01-12
PCT/KR2019/000204 WO2019139313A1 (en) 2018-01-12 2019-01-07 Stabilized pharmaceutical formulation comprising everolimus

Publications (2)

Publication Number Publication Date
CN111565714A CN111565714A (zh) 2020-08-21
CN111565714B true CN111565714B (zh) 2022-05-17

Family

ID=67219083

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980007209.1A Active CN111565714B (zh) 2018-01-12 2019-01-07 包含依维莫司的实现稳定化的药剂学制剂

Country Status (7)

Country Link
JP (1) JP7218372B2 (pt)
KR (1) KR102051806B1 (pt)
CN (1) CN111565714B (pt)
BR (1) BR112020014292A2 (pt)
EA (1) EA202091455A1 (pt)
MX (1) MX2020007434A (pt)
WO (1) WO2019139313A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111388455B (zh) * 2020-04-09 2022-09-02 沈阳药科大学 一种依维莫司口腔膜剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826882D0 (en) * 1998-12-07 1999-01-27 Novartis Ag Organic compounds
WO2008016633A2 (en) * 2006-08-02 2008-02-07 Ariad Gene Therapeutics, Inc. Combination therapy
EP1952807A1 (en) * 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
US20120064143A1 (en) * 2008-11-11 2012-03-15 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
WO2013050419A1 (en) * 2011-10-06 2013-04-11 Novartis Ag Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin
KR20140032586A (ko) * 2012-09-06 2014-03-17 한국원자력의학원 Ｐｔｅｎ 기능저하에 의한 ｅｇｆｒ-ｔｋｉ 저해제-내성 폐암의 방사선 치료용 약학 조성물
TW201503912A (zh) * 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
MX367121B (es) * 2013-08-02 2019-08-06 Laboratorio Raam De Sahuayo S A De C V Composición sólida estable de inmunosupresores.
KR20150138104A (ko) * 2014-05-30 2015-12-09 동아에스티 주식회사 베포타스틴과 글리세릴베헤네이트를 포함하는 약제학적 제제
CN104398483B (zh) 2014-11-05 2018-01-26 上海医药集团青岛国风药业股份有限公司 一种奥美沙坦酯片及其制备工艺
CN105106145A (zh) * 2015-08-27 2015-12-02 济川药业集团有限公司 一种依维莫司片剂及其制备方法
US20190022073A1 (en) 2015-09-03 2019-01-24 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
JP2018111662A (ja) 2017-01-12 2018-07-19 ニプロ株式会社 エベロリムス製剤

Also Published As

Publication number Publication date
JP7218372B2 (ja) 2023-02-06
CN111565714A (zh) 2020-08-21
EA202091455A1 (ru) 2020-10-05
MX2020007434A (es) 2022-04-27
WO2019139313A1 (en) 2019-07-18
BR112020014292A2 (pt) 2020-12-08
JP2021510374A (ja) 2021-04-22
KR102051806B1 (ko) 2019-12-04
KR20190086212A (ko) 2019-07-22

Similar Documents

Publication Publication Date Title
KR101290925B1 (ko) 코팅된 정제 제형 및 방법
US12059397B2 (en) Calcium lactate compositions and methods of use
CN107595784B (zh) 他克莫司缓释药物组合物
UA81265C2 (en) Granulate formulation of the rapamycin ester cci-779 and process for the preparation thereof
BRPI0212922B1 (pt) Composição farmacêutica na forma de um comprimido dispersável compreendendo uma dispersão sólida de 40-o-(2-hidroxietil)-rapamicina, seu processo de preparação e uso da dita composição
AU2022241561A1 (en) Dosage form compositions comprising an inhibitor of Bruton's tyrosine kinase
US20230190732A1 (en) Pharmaceutical composition containing nitroxoline prodrug, and preparation method and application therefor
JP7470161B2 (ja) タクロリムスを含む徐放性薬剤学的製剤
WO2011051967A2 (en) Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
CN115624525A (zh) 一种他克莫司缓释药物组合物及其制备方法
CN111565714B (zh) 包含依维莫司的实现稳定化的药剂学制剂
TW201944996A (zh) 用於溶解包含阿哌沙班的藥學配方及其製備方法
EA028329B1 (ru) Содержащая прасугрель стабильная фармацевтическая лекарственная форма с немедленным высвобождением для перорального введения, способ получения и применения
CN103330694A (zh) 口服制剂
AU2003272857B2 (en) A controlled release system containing temozolomide
CN101632662A (zh) 一种西罗莫司制剂及其制备方法
CN109125320B (zh) 一种吡啶类化合物的药物组合物
EA047528B1 (ru) Стабилизированный фармацевтический состав, содержащий эверолимус
EP3576735A1 (en) Pharmaceutical composition of everolimus
TW201300106A (zh) 治療ｈｃｖ感染之醫藥組合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40031628

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant